National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Selpercatinib (Retsevmo®) for advanced RET fusion-positive thyroid cancer. HTA ID: 21020b

Selpercatinib is indicated for the treatment of adult patients with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with lenvatinib and/or sorafenib.


NCPE Assessment Process Complete
Rapid review commissioned 08/06/2021
Rapid review completed 07/07/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/07/2021
Pre-submission consultation with Applicant 08/11/2021
Current Status Awaiting HTA submission from Applicant